Kernan WN, et al. - The researchers aimed to investigate whether patients who were at higher risk for recurrent stroke or myocardial infarction (MI) derived more benefit from pioglitazone hydrochloride, among patients with an ischemic stroke or transient ischemic attack and insulin resistance compared with patients at lower risk. Compared with patients at lower risk, patients at higher risk for stroke or MI derived a greater absolute benefit from pioglitazone after an ischemic stroke or transient ischemic attack. However, the risk of fracture was also higher.